Melese Daniel Molla, Aragaw Abebaye, Mekonen Wondyefraw
Department of Biomedical Science, Asrat Woldeyes Health Science Campus, Debre Berhan University, Debre Berhan, Ethiopia.
Department of Physiology, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Epilepsia Open. 2024 Dec;9(6):2101-2111. doi: 10.1002/epi4.13066. Epub 2024 Oct 30.
To evaluate the effect of vagus nerve stimulation (VNS) on seizure control, cognitive functions, and quality of life in individuals with drug-resistant epilepsy.
An extensive search of electronic databases was carried out in order to carry out this systematic review. The databases Google Scholar, Embase, PubMed, and the Cochrane Library were searched first to carryout gray literature. To reduce the quantity of pointless studies in the advanced search, the search is limited to "human studies" and "English language" publications only. Combining keywords and Medical Subject Headings (MeSH) terms like ("Vagus Nerve Stimulation" OR "VNS") AND ("Epilepsy" OR "Seizure Control") AND ("Cognitive Function" OR "Quality of Life"). Studies that have been published up to November 30/2023 were included.
The search strategy yielded a total of 392 relevant studies. The mean age of participant's ranges from 11 years to 33 years. The duration of follow-up ranging from 6 to 36 months. Eleven studies were included in the review. The mean≥50% response rate after VNS therapy was 56.94% ranged from 48.90% to 83.00%. Four and three studies provided information about Quality of Life in Epilepsy Inventory (QOLIE-31) and The Liverpool Seizure Severity Scale (LSSS) questionnaires respectively.
Epilepsy is a chronic disease characterized by sudden abnormal discharge of brain neurons, which leads to transient brain dysfunction and the presence of spontaneous recurrent seizures. Vagus nerve stimulation has recently been proposed as a potential tool in the treatment of seizure, depressive symptoms, and cognitive impairments. There has been variation in the effects of VNS treatment on seizure control, cognitive functions, and quality of life among patients with drug-resistant epilepsy. So, a comprehensive review of exciting literature is important to see the pooled effect. Previous systematic review and meta-analysis papers were mostly randomized control trial type with specific diseases. The use of a wider variety of study designs than only randomized controlled trials is important. So, we included retrospective and prospective cohort studies in addition to randomized control trials. This enables a more thorough assessment of the connection between quality of life, cognitive function, and vagus nerve stimulation. In addition, the paper looks at a wide range of disease kinds and patterns. We have established a uniform and comprehensive approach throughout the selected studies by mandating the inclusion of all three crucial parameters: vagus nerve stimulation, cognitive function, and quality of life.
This systematic review examined 392 relevant studies on vagus nerve stimulation (VNS) therapy, with participants ranging from 11 to 33 years old and follow-up durations of 6-36 months. Eleven studies were included, and the mean response rate after VNS therapy was 56.94%, ranging from 48.90% to 83.00%. The review also reported on quality of life and cognitive function, and seizure severity frequency result from several studies.
评估迷走神经刺激(VNS)对耐药性癫痫患者癫痫控制、认知功能和生活质量的影响。
为进行这项系统评价,对电子数据库进行了广泛检索。首先检索了谷歌学术、Embase、PubMed和考克兰图书馆数据库以获取灰色文献。为减少高级检索中无意义研究的数量,检索仅限于“人体研究”和“英文”出版物。结合关键词和医学主题词(MeSH),如(“迷走神经刺激”或“VNS”)与(“癫痫”或“癫痫控制”)以及(“认知功能”或“生活质量”)。纳入截至2023年11月30日发表的研究。
检索策略共产生392项相关研究。参与者的平均年龄在11岁至33岁之间。随访时间为6至36个月。该评价纳入了11项研究。VNS治疗后平均≥50%的缓解率为56.94%,范围在48.90%至83.00%之间。四项和三项研究分别提供了癫痫生活质量量表(QOLIE - 31)和利物浦癫痫严重程度量表(LSSS)问卷相关的生活质量信息。
癫痫是一种以脑神经元突然异常放电为特征的慢性疾病,可导致短暂性脑功能障碍和自发性反复癫痫发作。迷走神经刺激最近被提议作为治疗癫痫发作、抑郁症状和认知障碍的一种潜在工具。VNS治疗对耐药性癫痫患者的癫痫控制、认知功能和生活质量的影响存在差异。因此,对现有文献进行全面综述以了解综合效应很重要。以往的系统评价和荟萃分析论文大多是特定疾病的随机对照试验类型。使用比仅随机对照试验更广泛的研究设计很重要。所以,除随机对照试验外,我们还纳入了回顾性和前瞻性队列研究。这能够更全面地评估生活质量、认知功能与迷走神经刺激之间的联系。此外,本文研究了广泛的疾病类型和模式。我们通过要求纳入所有三个关键参数:迷走神经刺激、认知功能和生活质量,在所选研究中建立了统一而全面的方法。
这项系统评价考察了392项关于迷走神经刺激(VNS)治疗的相关研究,参与者年龄在11至33岁之间,随访时间为6至36个月。纳入了11项研究,VNS治疗后的平均缓解率为56.94%,范围在48.90%至83.00%之间。该评价还报告了几项研究中的生活质量、认知功能以及癫痫严重程度频率结果。